Parkinson disease: The controversy of levodopa toxicity in Parkinson disease

Nature Reviews Neurology

Volumn 8, Issue 1, 2012, Pages 8-10

  Zesiewicz, Theresa A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; HYDROGEN PEROXIDE; IOMETOPANE; LEVODOPA; PLACEBO;

ARTICLE; AUTOOXIDATION; CELL DENSITY; CHRONIC DRUG ADMINISTRATION; DISEASE DURATION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; DYSKINESIA; HUMAN; LEWY BODY; MONOTHERAPY; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; UNIFIED PARKINSON DISEASE RATING SCALE;

ANTIPARKINSON AGENTS; BRAIN; HUMANS; LEVODOPA; NEURONS; PARKINSON DISEASE;

EID: 84555195663     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2011.199     Document Type: Article

References (10)

1. Spencer, J. P. et al. Evaluation of the pro-oxidant and antioxidant actions of l-DOPA and dopamine in vitro: Implications for Parkinson's disease. Free Radic. Res. 24, 95-105 (1996). (Pubitemid 26035630)
2. Murer, M. G. et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 43, 561-575 (1998). (Pubitemid 28225547)
3. Shin, J. Y., Park, H. J., Ahn, Y. H. & Lee, P. H. Neuroprotective effect of l-DOPA on dopaminergic neurons is comparable to pramipexole in MPTP-treated animal model of Parkinson's disease: A direct comparison study. J. Neurochem. 111, 1042-1050 (2009).
4. Parkkinen, L. et al. Does levodopa accelerate the pathologic process in Parkinson disease brain. Neurology 77, 1420-1426 (2011).
5. Jenner, P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 (Suppl. 3), S26-S38 (2003). (Pubitemid 36368560)
6. Olanow, C. W., Gauger, L. L. & Cedarbaum, J. M. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann. Neurol. 29, 556-559 (1991).
7. Fahn, S. et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351, 2498-2508 (2004).
8. Rascol, O. et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342, 1484-1491 (2000). (Pubitemid 30318272)
9. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 284, 1931-1938 (2000).
10. Constantinescu, R., Romer, M., McDermott, M. P., Kamp, C. & Kieburtz, K. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov. Disord. 22. 1317-1319 (2007). (Pubitemid 47325041)